Trial Profile
A Phase IIa, Randomized, Multicenter, Double-Blind, Active Comparator- and Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of MK8998 in Acutely Psychotic Patients With Schizophrenia.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Suvecaltamide (Primary) ; Olanzapine
- Indications Schizophrenia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 22 Jun 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
- 22 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Jun 2010 Actual patient number (216) added as reported by ClinicalTrials.gov.